Agios Pharmaceuticals (AGIO)
(Delayed Data from NSDQ)
$33.00 USD
+0.08 (0.24%)
Updated May 10, 2024 04:00 PM ET
After-Market: $33.03 +0.03 (0.09%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
Price, Consensus and EPS Surprise
AGIO 33.00 +0.08(0.24%)
Will AGIO be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for AGIO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AGIO
Wall Street Analysts See a 26.01% Upside in Agios Pharmaceuticals (AGIO): Can the Stock Really Move This High?
Agios (AGIO) Q1 Earnings Surpass, Sales Miss Estimates
AGIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Misses Revenue Estimates
Analysts Estimate Bio-Rad Laboratories (BIO) to Report a Decline in Earnings: What to Look Out for
Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for
Other News for AGIO
Agios Pharma (AGIO) Gets a Buy from RBC Capital
Agios to Present at the BofA Securities 2024 Health Care ConferenceĀ on May 16, 2024
Agios to Present at the RBC Capital Markets Global Healthcare ConferenceĀ on May 14, 2024
RBC Capital Sticks to Their Buy Rating for Agios Pharma (AGIO)
Agios Pharmaceuticals Inc (AGIO) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...